ACE-031

ACE-031 belongs to the soluble decoy-receptor (ligand-trap) class built on the extracellular domain of the activin receptor type IIB (ActRIIB / ACVR2B). The pathway context was established by Lee and McPherron (2001), who characterized myostatin signaling through the type II activin receptors and the antagonism of that signaling by endogenous binding partners such as follistatin and the myostatin propeptide, and showed that a dominant-negative ActRIIB construct altered the muscle-regulatory program in vivo. Lee and colleagues (2005) extended the framework by examining a soluble ActRIIB trap and reporting that ligands beyond myostatin - including activins and GDF-11 - contribute to the same receptor-level regulation, since the response was attenuated but not eliminated in myostatin-null systems. Sako and colleagues (2010) provided the biophysical characterization of an ActRIIB-Fc chimera using surface plasmon resonance, mapping the relative binding of GDF-8, GDF-11, activin A, and the BMP ligands and identifying determinants of ligand specificity within the receptor C-terminus, including the role of a single residue (Leu79). Together these studies frame ACE-031 as a broad type-II-ligand trap rather than a myostatin-selective tool - a distinction that matters when designing experiments where selectivity is the variable of interest.

ACE-031 is a biologic, not a synthetic peptide. Analytical work by Reichel and colleagues (2025) characterized the molecule's architecture by gel electrophoresis: a disulfide-linked homodimer whose two 343-residue chains each consist of the ACVR2B extracellular domain (residues 1-115), a triglycyl linker, and a human IgG1 Fc region, with seven intrachain disulfide bridges per chain, two interchain bridges joining the monomers, and three N-glycosylation sites per chain. The same work noted that research material supplied under the ACE-031 name can be heterogeneous - some preparations correspond to full-length ACVR2B rather than the engineered extracellular-domain Fc fusion - underscoring why identity and purity verification (mass spectrometry / peptide mapping, SDS-PAGE and size-exclusion analysis, endotoxin testing) are emphasized for research material. Reported molecular-weight figures vary with glycoform and method; the peer-reviewed value of roughly 58.4 kDa per glycosylated monomer is treated as primary, with lot-specific confirmation against the Certificate of Analysis.

A substantial preclinical literature has examined soluble ActRIIB-Fc constructs across model systems. Cadena and colleagues (2010) studied ACE-031 in healthy mice and reported that skeletal-muscle changes were independent of fiber type. Pistilli and colleagues examined a soluble ActRIIB receptor/Fc construct in the mdx dystrophic mouse model (2011) and in a hypoxia-exposure model (2010), assessing muscle and force-production measures. Zhou and colleagues (2010) used a soluble ActRIIB decoy in skeletal- and cardiac-muscle wasting (cachexia) models and examined the ubiquitin-proteasome system and satellite-cell compartment. Koncarevic and colleagues (2010) examined a soluble activin receptor type IIB in androgen-deprivation model systems of bone and muscle tissue. A point of experimental nuance runs through this body of work: several of these reagents use a murine IgG Fc rather than the human IgG1 Fc of the engineered Fc-fusion construct, so they are functional analogs of ACE-031 rather than the identical molecule, and findings are best attributed to the specific engineered construct studied. For mechanistic contrast, Lach-Trifilieff and colleagues (2014) characterized antibody-mediated blockade of the activin type II receptors, distinguishing that approach from the ligand-trap strategy.

ACE-031 has been examined in registered human studies. Attie and colleagues (2013) reported a Phase 1 single-ascending-dose study in healthy postmenopausal volunteers (registry entries A031-01 and A031-02), assessing pharmacokinetic and imaging-based measurement endpoints (DXA and MRI). Campbell and colleagues (2017) reported a Phase 2 randomized, placebo-controlled study in a Duchenne muscular dystrophy research population (registry entry A031-03, with an open-label extension A031-06), examining the measurement endpoints defined in that study. These studies are referenced here for their design and the measurement contexts they examined; the references list links the corresponding ClinicalTrials.gov registrations.

Review literature places ACE-031 within the broader set of myostatin-pathway and activin-pathway modulators. Lee (2023) reviewed the underlying receptor biology and the soluble-receptor, antibody, and propeptide strategies for engaging it; Suh and Lee (2020) compared these strategies in a musculoskeletal-research context; and Rybalka and colleagues (2020) reviewed the myostatin-inhibitor literature in muscular-dystrophy research. A recurring theme across the reviews is selectivity: because ACE-031 traps multiple type II receptor ligands rather than myostatin alone, it is used in research specifically when broad ligand blockade - rather than single-ligand inhibition - is the intended experimental variable, and engineered variants of the receptor-trap class have been explored to narrow the ligand profile.